BACKGROUND: The impact of one-stage polypectomy (removal of all neoplasms during diagnostic colonoscopy) versus two-stage polypectomy (removal of all neoplasms during therapeutic colonoscopy following the initial diagnostic colonoscopy) on the development of metachronous neoplasms is poorly understood. Our aim was to compare the effects of one- versus two-stage polypectomy on the development of metachronous neoplasms METHODS: We retrospectively reviewed the medical records of 249 patients in a tertiary center who underwent one-stage polypectomy, which was followed by one or more surveillance colonoscopy. The development of metachronous neoplasm in this group was compared with that of an age- and sex-matched two-stage polypectomy group consisting of 498 patients RESULTS: In total, 346 (46.3 %) patients developed any metachronous neoplasm and 29 (3.9 %) patients developed advanced metachronous neoplasm. The 5 years cumulative incidences of any and advanced metachronous neoplasm were 46.2 and 5.0 %, respectively, in the one-stage group, which are not significantly different from the rates of 50.7 and 3.3 % in the two-stage group (p = 0.94 and 0.30, respectively). The only significant risk factor for developing any metachronous neoplasm was ≥ 3 neoplasms at the baseline polypectomy [hazard ratio (HR) 1.75; 95 % confidence interval (CI) 1.41-2.17; p < 0.001]. The only significant risk factor for developing advanced metachronous neoplasm was advanced neoplasm at the baseline polypectomy (HR 2.37; 95 % CI 1.16-4.84; p = 0.01). One- and two-stage polypectomy did not affect the development rates of metachronous neoplasm CONCLUSIONS: The risks of developing metachronous neoplasm may be similar following one- and two-stage polypectomy.
BACKGROUND: The impact of one-stage polypectomy (removal of all neoplasms during diagnostic colonoscopy) versus two-stage polypectomy (removal of all neoplasms during therapeutic colonoscopy following the initial diagnostic colonoscopy) on the development of metachronous neoplasms is poorly understood. Our aim was to compare the effects of one- versus two-stage polypectomy on the development of metachronous neoplasms METHODS: We retrospectively reviewed the medical records of 249 patients in a tertiary center who underwent one-stage polypectomy, which was followed by one or more surveillance colonoscopy. The development of metachronous neoplasm in this group was compared with that of an age- and sex-matched two-stage polypectomy group consisting of 498 patients RESULTS: In total, 346 (46.3 %) patients developed any metachronous neoplasm and 29 (3.9 %) patients developed advanced metachronous neoplasm. The 5 years cumulative incidences of any and advanced metachronous neoplasm were 46.2 and 5.0 %, respectively, in the one-stage group, which are not significantly different from the rates of 50.7 and 3.3 % in the two-stage group (p = 0.94 and 0.30, respectively). The only significant risk factor for developing any metachronous neoplasm was ≥ 3 neoplasms at the baseline polypectomy [hazard ratio (HR) 1.75; 95 % confidence interval (CI) 1.41-2.17; p < 0.001]. The only significant risk factor for developing advanced metachronous neoplasm was advanced neoplasm at the baseline polypectomy (HR 2.37; 95 % CI 1.16-4.84; p = 0.01). One- and two-stage polypectomy did not affect the development rates of metachronous neoplasm CONCLUSIONS: The risks of developing metachronous neoplasm may be similar following one- and two-stage polypectomy.
Authors: Brian Bressler; Lawrence F Paszat; Zhongliang Chen; Deanna M Rothwell; Chris Vinden; Linda Rabeneck Journal: Gastroenterology Date: 2007-01 Impact factor: 22.682
Authors: Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church Journal: Am J Gastroenterol Date: 2012-06-19 Impact factor: 10.864
Authors: R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe Journal: Gut Date: 2000-08 Impact factor: 23.059
Authors: Nancy N Baxter; Meredith A Goldwasser; Lawrence F Paszat; Refik Saskin; David R Urbach; Linda Rabeneck Journal: Ann Intern Med Date: 2008-12-15 Impact factor: 25.391
Authors: Peter B Cotton; Valerie L Durkalski; Benoit C Pineau; Yuko Y Palesch; Patrick D Mauldin; Brenda Hoffman; David J Vining; William C Small; John Affronti; Douglas Rex; Kenyon K Kopecky; Susan Ackerman; J Steven Burdick; Cecelia Brewington; Mary A Turner; Alvin Zfass; Andrew R Wright; Revathy B Iyer; Patrick Lynch; Michael V Sivak; Harold Butler Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Daniele Regge; Cristiana Laudi; Giovanni Galatola; Patrizia Della Monica; Luigina Bonelli; Giuseppe Angelelli; Roberto Asnaghi; Brunella Barbaro; Carlo Bartolozzi; Didier Bielen; Luca Boni; Claudia Borghi; Paolo Bruzzi; Maria Carla Cassinis; Massimo Galia; Teresa Maria Gallo; Andrea Grasso; Cesare Hassan; Andrea Laghi; Maria Cristina Martina; Emanuele Neri; Carlo Senore; Giovanni Simonetti; Silvia Venturini; Giovanni Gandini Journal: JAMA Date: 2009-06-17 Impact factor: 56.272
Authors: C Daniel Johnson; Mei-Hsiu Chen; Alicia Y Toledano; Jay P Heiken; Abraham Dachman; Mark D Kuo; Christine O Menias; Betina Siewert; Jugesh I Cheema; Richard G Obregon; Jeff L Fidler; Peter Zimmerman; Karen M Horton; Kevin Coakley; Revathy B Iyer; Amy K Hara; Robert A Halvorsen; Giovanna Casola; Judy Yee; Benjamin A Herman; Lawrence J Burgart; Paul J Limburg Journal: N Engl J Med Date: 2008-09-18 Impact factor: 91.245
Authors: Gottumukkala S Raju; Phillip J Lum; William A Ross; Selvi Thirumurthi; Ethan Miller; Patrick M Lynch; Jeffrey H Lee; Manoop S Bhutani; Mehnaz A Shafi; Brian R Weston; Mala Pande; Robert S Bresalier; Asif Rashid; Lopa Mishra; Marta L Davila; John R Stroehlein Journal: Gastrointest Endosc Date: 2016-02-06 Impact factor: 9.427